However, Mac1, as a CD30‐expressing cell line isolated from a primary cutaneous T‐cell lymphoma patient (Ehrentraut et al, 2013), is less representative of aggressive L‐CTCL disease, and it might represent a “rare case.” Other cell lines, such as Hut78 or Myla, even though they carry activating JAK mutations, were resistant to JAK blockers but still responsive to IQDMA, emphasizing the importance of upregulated STAT3/5 gene dosage and the action of upstream kinases culminating in enhanced nuclear STAT3/5 protein levels. Here, STAT3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.